ChinaBio Today Report / Apr 29, 2018 Innovent of Suzhou announced its series E financing of $150 million. Capital Group Private Markets (CGPM) is leading this investment with $90 million,…
Hua Medicine, a clinical-stage drug development company developing novel therapies for the treatment of Type 2 diabetes, announced the closing of a combined Series D & Series E financing of…
Hong Kong, Shenzhen and San Francisco, January 7, 2018 – Ally Bridge Group (“ABG”), a global healthcare-focused investment firm, has entered into a strategic partnership with LifeTech Scientific Corporation (SEHK:…
